A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis

Study Withdrawn Prior to Determining Official Title

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00375596

Enrollment

Registered

2006-09-13

Start date

Unknown

Completion date

Unknown

Last updated

2015-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis

Brief summary

This study will evaluate the safety and efficacy of a new allergy medication

Detailed description

Study withdrawn prior to determining study details

Interventions

DRUGKetotifen/vasoconstrictor

Study design

Intervention model

PARALLEL

Eligibility

Sex/Gender

ALL

Age

6 Years to No maximum

Healthy volunteers

Inclusion criteria

* Be at least 6 years of age, of any race, or either gender. * Have a positive allergic history of ocular allergies and a positive skin test reaction to cat hair/dander, ragweed, tree and/or grass pollen within the past 24 months. * Have a calculated best-corrected visual acuity of 0.6 logMar or better in each eye as measured using an ETDRS chart. * Positive bilateral CAC reaction at Visit 1 & 2.

Exclusion criteria

* Have any known contraindications, allergies, or sensitivities to the use of any of the study medications, or their components. * Any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters * Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye at the baseline slit-lamp exam of any visit

Design outcomes

Primary

Measure	Time frame	Description
Safety and efficacy of a new allergy medication	0	STUDY WITHDRAWN PRIOR TO OUTCOME DETERMINATION

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026